Department of Medicine, University of Toronto, Ontario, Canada.
J Infect Dis. 2012 May 15;205(10):1534-8. doi: 10.1093/infdis/jis243. Epub 2012 Mar 23.
A cohort of human immunodeficiency virus (HIV)-infected individuals with documented vaccine-induced hepatitis B surface antibody (HBsAb) seroconversion was evaluated retrospectively to determine factors associated with loss of protective levels of HBsAb. After a median follow-up of 43 months, 111 of the 152 participants (73%) maintained protective levels of HBsAb. HIV RNA suppression at vaccination was associated with persistence of protective levels of HBsAb (odds ratio, 3.83; P < .01). Booster doses were provided for those with loss of protective antibody levels, and hepatitis B virus-specific immune memory, as evaluated with T-cell proliferation assays, was poor despite the observation that boosters successfully reinduced protective levels of HBsAb.
一项对已确诊有乙型肝炎表面抗体（HBsAb）疫苗诱导血清学转换的人类免疫缺陷病毒（HIV）感染个体的队列进行了回顾性评估，以确定与 HBsAb 保护性水平丧失相关的因素。中位随访 43 个月后，152 名参与者中的 111 名（73%）维持了 HBsAb 的保护性水平。疫苗接种时 HIV RNA 抑制与 HBsAb 保护性水平的持续存在相关（比值比，3.83；P<.01）。对于保护性抗体水平丧失的患者，给予了加强剂量，并且尽管观察到加强剂量成功地重新诱导了 HBsAb 的保护性水平，但使用 T 细胞增殖测定评估乙型肝炎病毒特异性免疫记忆很差。
